- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Listing of subscription rights and paid subscription shares of Biosergen AB | 266 | GlobeNewswire | With effect from August 12, 2026, the subscription rights in Biosergen AB will be traded on First North Growth Market. Trading will continue up until and including August 21, 2026.
... ► Artikel lesen | |
| 10.08. | Biosergen AB: Biosergen publishes information document regarding rights issue | 282 | GlobeNewswire (Europe) | The Board of Directors of Biosergen AB (publ) ("Biosergen" or the "Company") has today, on 10 August 2026, published an information document in connection with the rights issue of shares of approximately... ► Artikel lesen | |
| 06.08. | Biosergen AB: Bulletin from the extraordinary general meeting of Biosergen AB (publ) | 265 | GlobeNewswire (Europe) | Biosergen AB, reg. no. 559304-1295 ("Biosergen" or the "Company"), held its extraordinary general meeting today, 6 August 2026, at BAHR Advokatbyrå, Birger Jarlsgatan 16, 114 34 Stockholm, where the... ► Artikel lesen | |
| 06.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2026 | 268 | Xetra Newsboard | Das Instrument W1M SG1J24887775 SINGAPORE SHIPPING SD-,1 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2026 und ex Kapitalmassnahme am 07.08.2026 The instrument W1M SG1J24887775 SINGAPORE SHIPPING... ► Artikel lesen | |
| 16.07. | BIOSERGEN AB: Flerie publishes merger document | 1 | Cision News | ||
| 08.07. | Notice of extraordinary general meeting in Biosergen AB | 2 | Cision News | ||
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 30.06. | Biosergen AB: Bulletin from the annual general meeting of Biosergen AB | 192 | GlobeNewswire (Europe) | Biosergen AB reg. no. 559304-1295 ("Biosergen" or the "Company") held its annual general meeting today, 30 June 2026, at BAHR Advokatbyrå, Birger Jarlsgatan 16, 114 34 Stockholm, where the below resolutions... ► Artikel lesen | |
| 29.06. | The observation status for Biosergen AB is updated | 225 | GlobeNewswire | On April 10, 2026, the shares in Biosergen AB (the "Company") were given observation status with reference to information that the Company's board of directors had resolved to pause the development... ► Artikel lesen | |
| 26.06. | Biosergen AB: Statement from the Board of Directors of Biosergen regarding the merger with Flerie | 1.094 | GlobeNewswire (Europe) | This statement is made by the Board of Directors of Biosergen AB (the "Company" or "Biosergen") pursuant to Section II.19 of the Swedish takeover rules for certain trading platforms (the "Takeover... ► Artikel lesen | |
| 26.06. | Biosergen AB: The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie | 308 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 26.06. | BIOSERGEN AB: Biosergen Publishes 2025 Annual Report | 1 | Cision News | ||
| 26.06. | Flerie AB: Flerie and Biosergen have agreed on a merger plan - Flerie's first new investment since its listing on Nasdaq Stockholm | 339 | GlobeNewswire (Europe) | Today, on 26 June 2026, Flerie AB (publ) ("Flerie") and Biosergen AB ("Biosergen") (together the "Companies") jointly announce that the Board of Directors of Flerie and the Board of Directors of Biosergen... ► Artikel lesen | |
| 11.06. | Notice of annual general meeting in Biosergen AB | 2 | Cision News | ||
| 10.04. | Biosergen AB receives observation status | 341 | GlobeNewswire | On April 4, 2026, Biosergen AB ("the Company") disclosed that the Company's board of directors had resolved to pause the development of BSG005 and that the board of directors is exploring the possibility... ► Artikel lesen | |
| 04.04. | BIOSERGEN AB: Biosergen Pauses Development of BSG005 | 3 | Cision News | ||
| 10.02. | Biosergen AB: Biosergen publishes interim report for the fourth quarter 2025 | 323 | GlobeNewswire (Europe) | February 10, 2026: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the fourth quarter 2025. The interim report is available as an attached document and on the company... ► Artikel lesen | |
| 01.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 01.12.2025 | 785 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.12.2025
Aktien
1 IT0005678104 Kaleon S.p.A.
2 IM00BYYPQX37... ► Artikel lesen | |
| 28.11.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.11.2025 | 1.289 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 28.11.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.11.2025ISIN NameCA38940L2057 GRAYCLIFF... ► Artikel lesen | |
| 28.11.25 | XFRA ISIN CHANGE | 596 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA60283T2074 Mineral Hill Industries Ltd. 28.11.2025 CA38077F1045 Gold Strategy Inc. 01.12.2025 Tausch 1:1US60855D3098 Moleculin... ► Artikel lesen | |
| 28.11.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 28.11.2025 | 586 | Xetra Newsboard | Das Instrument 8N1 SE0016013460 BIOSERGEN AB EQUITY wird cum Kapitalmassnahme gehandelt am 28.11.2025 und ex Kapitalmassnahme am 01.12.2025 The instrument 8N1 SE0016013460 BIOSERGEN AB EQUITY is traded... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 12,780 | -4,27 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| PRAXIS PRECISION MEDICINES | 375,91 | +2,32 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,59 | +0,02 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,275 | -1,31 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| QIAGEN | 37,070 | -0,59 % | Qiagen überzeugt mit Zahlen, Micron ohne neuen Ausbruch und AST SpaceMobile verfehlt die Erwartungen - BÖRSE TO GO | Ein wenig wurde an den Börsen auch zu Beginn der neuen Woche noch aufgrund nachlassender Zinssorgen aufgeatmet. Begleitet wurde dies allerdings von eher unschönen Neuigkeiten aus Nahost, welche prompt... ► Artikel lesen | |
| VERA THERAPEUTICS | 31,600 | -0,09 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| CLIMB BIO | 17,450 | +6,79 % | Climb Bio, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 77,11 | +2,68 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 121,47 | +3,49 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| ARCUS BIOSCIENCES | 29,565 | +0,29 % | Arcus Biosciences GAAP EPS of -$0.72 beats by $0.17, revenue of $41M | ||
| ERASCA | 18,280 | -0,60 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 6,210 | +4,28 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 14,530 | +18,61 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | ||
| COGENT BIOSCIENCES | 37,890 | -0,16 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 16,350 | -0,61 % | MoonLake Immunotherapeutics AG: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial | Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with... ► Artikel lesen |
BIOSERGEN AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,232 Euro und damit -27,50 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.